Ad
related to: thrombocytopenia neonatal treatment options chart- View Prescribing Info
Click To Find Full Prescribing
Info For This Medication.
- About Chronic ITP
Learn More About What It Is
& How It Is Treated.
- Join For Exclusive Tips
Sign Up For Our Community Tips
Delivered To Your Doorstep & Inbox
- Connect With Coordinators
Click To Download Our Forms
Or Get Assistance.
- View Prescribing Info
Search results
Results from the WOW.Com Content Network
Neonatal alloimmune thrombocytopenia (NAITP, NAIT, NATP or NAT) is a disease that affects babies in which the platelet count is decreased because the mother's immune system attacks her fetus' or newborn's platelets. A low platelet count increases the risk of bleeding in the fetus and newborn.
Hemolytic disease of the fetus and newborn (HDN) is a condition where the passage of maternal antibodies results in the hemolysis of fetal/neonatal red cells. The antibodies can be naturally occurring such as anti-A, and anti-B, or immune antibodies developed following a sensitizing event. [ 12 ]
Hemolytic disease of the fetus and newborn (HDN) is a condition where the passage of maternal antibodies results in the hemolysis of fetal/neonatal red cells. The antibodies can be naturally occurring such as anti-A, and anti-B, or immune antibodies developed following a sensitizing event. [ 11 ]
One common definition of thrombocytopenia requiring emergency treatment is a platelet count below 50,000/μL. [5] Thrombocytopenia can be contrasted with the conditions associated with an abnormally high level of platelets in the blood – thrombocythemia (when the cause is unknown), and thrombocytosis (when the cause is known). [6] [7]
CAMT is diagnosed by a bone marrow biopsy and is often initially suspected to be fetal and neonatal alloimmune thrombocytopenia. [3] Two types of Congenital amegakaryocytic thrombocytopenia have been identified with type I being more severe. [1] Treatment is mostly supportive, consisting of multiple platelet transfusions.
Due to the high mortality of untreated TTP, a presumptive diagnosis of TTP is made even when only microangiopathic hemolytic anemia and thrombocytopenia are seen, and therapy is started. Transfusion is contraindicated in thrombotic TTP, as it fuels the coagulopathy. Since the early 1990s, plasmapheresis has become the treatment of choice for TTP.
Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis fetalis, [1] [2] is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules (one of the five main types of antibodies) produced by the mother pass through the placenta.
Unlike ITP, the platelet count in gestational thrombocytopenia rarely goes below 100,000, and a platelet count below 80,000 is even more rare (seen in less than 0.1% of cases of gestational thrombocytopenia). Also unlike ITP, gestational thrombocytopenia is not a cause of neonatal or maternal bleeding, or neonatal thrombocytopenia. [63]
Ad
related to: thrombocytopenia neonatal treatment options chart